secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001802768-22-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q3 2022: Adjusted Cash Receipts up 2% to $597M; raises FY 2022 guidance to $2,750-2,800M
--------------------------------------------------------------------------------

- Net cash from operating activities $539M (+15% YoY); Adjusted Cash Flow $441M (+26% YoY).
- Raised FY 2022 Adjusted Cash Receipts guidance to $2,750-2,800M, including $458M from Pfizer's Biohaven acquisition acceleration.
- Announced up to $3.0B YTD capital deployment, including R&D funding collaboration with Merck (MK-8189).
- Royalty receipts: Cystic fibrosis franchise $208M (+14%), Trelegy added $43M, Januvia/Janumet down 97% to $1M.
- Adjusted EBITDA $548M (+3%); operating costs 8% of Adjusted Cash Receipts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276822000043/0001802768-22-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276822000043/rprx-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001802768-22-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer